# US 2008/0306013 A1 · Illudin analogs useful as antitumor agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306013 A1
- Document ID: US20080306013A1
- Status: Published application
- Kind: A1
- Application number: 11/955,247
- Filed: 2007-12-12
- Published: 2008-12-11
- Earliest claimed: 1996-07-18
- Assignees: The Regents of the University of California
- Inventors: Trevor C. McMorris; Michael J. Kelner
- Web page: https://patentgrep.com/patent/US20080306013A1

## CPC

- C07D 317/72: spiro-condensed with carbocyclic rings
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07C 35/37: with a hydroxy group on a condensed system having three rings
- C07C 39/17: containing other rings in addition to the six-membered aromatic rings {, e.g. cyclohexylphenol}
- C07C 49/737: having three rings
- C07C 49/755: a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
- C07C 49/757: containing —CHO groups
- C07C 59/90: containing singly bound oxygen-containing groups
- C07C 69/007: Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
- C07C 69/96: Esters of carbonic or haloformic acids
- C07C 205/45: the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
- C07C 323/22: containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C 323/52: the carbon skeleton being acyclic and saturated
- C07C 323/58: with amino groups bound to the carbon skeleton
- C07D 233/54: having two double bonds between ring members or between ring members and non-ring members
- C07D 319/08: condensed with carbocyclic rings or ring systems
- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- C07H 15/18: Acyclic radicals, substituted by carbocyclic rings
- C07C 2601/14: The ring being saturated
- C07C 2603/94: containing "free" spiro atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention provides illudin analogs of the general formula (I): where R1 is (CH2)n—X—Y or H; n is 0 to 4; X is O or S or N or absent; and Y is an optionally substituted (C1-C8)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl or cyclo(C3-C6)alkyl optionally comprising one or more heteroatoms; a monosaccharide, an amino acid residue, or H when n is 2-4; R2 is absent; or R1 and R2 together comprise a 5-7 membered cyclic ring; R3 is (C1-C4)alkyl or H; R4 is H, SCH2CO2(C1-C4)alkyl, O—(C5-C12)aryl or —S—(C5-C12)aryl; R5 is H, OH or absent; R6 is (C1-C4)alkyl or absent; R7 is OH or OSi((C1-C4)alkyl)3; or R6 and R7 together are ethylenedioxy; R8 is optionally substituted (C1-C4)alkyl; and the bonds represented by --- are individually present or absent. The invention further provides dimers comprising analogs of formula (I).

## Claims

### Claim 1

A method to treat cancer comprising administering an effective amount of a compound of the formula
wherein
R1 is (CH2)n—X—Y,
where n is 0 to 4;
X is O or S or N, and
Y is —CH2OC(O)(C1-C4)alkyl, (C1-C8)alkyl optionally substituted with 1-2 OH or 1-2 halo, a monosaccharide, —CH2C(O)—O—(CH2)2—O—C(O)CH2SH, —(CH2)2—O—(CH2)2W where W is halo; —(C1-C8)alkyl-O—(C1-C8)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl or —C(O)O(C6-C10)aryl wherein the aryl group is optionally substituted with 1-2 OH, halo, (C1-C4)alkyl, or O(C1-C4)alkyl, —CH2CO2(C1-C4)alkyl, —CH2CO2H, Si((C1-C4)alkyl)3 or an amino acid residue;
R3 is H or (C1-C4)alkyl;
R4 is SCH2CO2(C1-C4)alkyl, —S—(C6-C10)aryl optionally substituted with halo, OH or (C1-C4)alkyl, or H;
R5 is H, OH or absent;
R6 is (C1-C4)alkyl or absent;
R7 is OH or —O(Si((C1-C4)alkyl)3; or
R6 and R7 together are ethylenedioxy;
R8 is (C1-C4)alkyl optionally comprising OH or halo;
the bond represented by ----- is present or absent; or
a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the cancer is lung cancer or hematopoietic cell cancer.

### Claim 2 (depends on 1)

A method of claim 1 wherein n is 1, the bond represented by ----- is present, and R5 is absent.

### Claim 3 (depends on 2)

A method of claim 2 wherein R3 is CH3, R4 is H, R6 is CH3, R7 is OH and R8 is CH3.

### Claim 4 (depends on 3)

A method of claim 3 wherein X is O.

### Claim 5 (depends on 4)

A method of claim 4 wherein Y is CH2OC(O)CH3.

### Claim 6 (depends on 4)

A method of claim 4 wherein Y is (C1-C4)alkyl.

### Claim 7 (depends on 6)

A method of claim 6 wherein Y is —CH2CH3.

### Claim 8 (depends on 4)

A method of claim 4 wherein Y is a (C1-C8)alkyl substituted by 2 OH.

### Claim 9 (depends on 8)

A method of claim 8 wherein Y is —CH2CH(OH)CH2OH.

### Claim 10 (depends on 4)

A method of claim 4 wherein Y is fructose.

### Claim 11 (depends on 4)

A method of claim 4 wherein Y is —(CH2)2Br.

### Claim 12 (depends on 4)

A method of claim 4 wherein Y is —(CH2)2OH.

### Claim 13 (depends on 4)

A method of claim 4 wherein Y is —C(CH3)2-O—(C1-C4)alkyl.

### Claim 14 (depends on 13)

A method of claim 13 wherein Y is —C(CH3)2-O—CH3.

### Claim 15 (depends on 4)

A method of claim 4 wherein Y is —C(O)—O-Phenyl.

### Claim 16 (depends on 3)

A method of claim 3 wherein X is S.

### Claim 17 (depends on 16)

A method of claim 16 wherein Y is phenyl substituted with OH or CH3.

### Claim 18 (depends on 16)

A method of claim 16 wherein Y is benzyl.

### Claim 19 (depends on 16)

A method of claim 16 wherein Y is —CH2CO2CH3.

### Claim 20 (depends on 16)

A method of claim 16 wherein Y is —CH2CO2H.

### Claim 21 (depends on 16)

A method of claim 16 wherein Y is (C1-C8)alkyl substituted by 2 OH.

### Claim 22 (depends on 21)

A method of claim 21 wherein Y is —CH2CH(OH)CH2OH.

### Claim 23 (depends on 1)

A method of claim 1 wherein n is 1, the bond represented by --- is absent, X is S; Y is CH2CO2CH3; R3 is CH3; R4 is S, CO2CH3; R6 is CH3 and R7 is OH.

### Claim 24 (depends on 23)

A method of claim 23 wherein R5 is H.

### Claim 25 (depends on 23)

A method of claim 23 wherein R5 is OH.

### Claim at position 26

26-55. (canceled)

### Claim 56 (depends on 1)

The method of claim 1 wherein the subject is a human cancer patient.

### Claim 57

(canceled)

### Claim 58 (depends on 1)

The method of claim 1, wherein the hematopoietic cell cancer comprises B-cell leukemia, B-cell lymphoma, myeloma, T-cell leukemia, T-cell lymphoma, small leukemia, and small cell lymphoma.
